Literature DB >> 23816381

Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence.

Patrick B Garvey1, Justin H Booth, Donald P Baumann, Kathy A Calhoun, Jun Liu, Raphael E Pollock, Charles E Butler.   

Abstract

BACKGROUND: The propensity of desmoid tumors to develop in scars has led some surgeons to limit the complexity of desmoid defect reconstruction as a strategy for avoiding desmoid recurrence. We hypothesized that desmoid recurrence rates are similar despite the magnitude of reconstruction. STUDY
DESIGN: We retrospectively compared recurrence rates between patients who underwent reconstruction and patients who underwent primary closure without reconstruction after desmoid tumor resection in consecutive patients for 15 years. Univariate and multivariate regression analyzed associations between patient, tumor, and treatment characteristics and outcomes.
RESULTS: We included 164 consecutive patients (80 [49%] reconstructions vs 84 [51%] primary closures). Mean follow-up duration was 7.1 ± 4.5 years. Patients who underwent reconstruction had more desmoids in an area of earlier trauma or surgery (p < 0.001), greater defect volume (p < 0.01), longer operative time (p < 0.001) and hospital stay (p < 0.001), and more postoperative complications (p = 0.015) compared with the primary closure group. Despite these differences, desmoid recurrence rates were similar for the reconstruction and primary closure groups (30% and 29%, respectively; p = 0.7), as was mean time to tumor recurrence, and no tumors recurred within flap donor sites. Multivariate regression analysis demonstrated the 45F mutation to be the only independent predictor of recurrence (hazard ratio = 1.87; p = 0.04).
CONCLUSIONS: Rates of desmoid recurrence in resection defects are similar for primary closures and complex reconstructions. Therefore, surgeons should not limit the magnitude of reconstructions in an attempt to avoid tumor recurrence. However, given the propensity of desmoids to recur, reconstructions should allow for the possibility of future resections and reconstructions, particularly in tumors with 45F gene mutations.
Copyright © 2013 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23816381     DOI: 10.1016/j.jamcollsurg.2013.04.038

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  5 in total

1.  Large desmoid-type fibromatosis of the shoulder girdle: operative approach selection and clinic outcome.

Authors:  Fan Tang; Li Min; Rui Yin; Wenli Zhang; Yong Zhou; Yi Luo; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Int Orthop       Date:  2015-01-21       Impact factor: 3.075

2.  [Long-term effectiveness of "West China Classification" guided surgical treatment of desmoid-type fibromatosis in shoulder girdle].

Authors:  Sisi Zhou; Fan Tang; Li Min; Yi Luo; Yong Zhou; Hong Duan; Chongqi Tu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-06-15

3.  Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection.

Authors:  Jacob E Mandel; DaeHee Kim; Hooman Yarmohammadi; Etay Ziv; Mary L Keohan; Sandra P D'Angelo; Mrinal M Gounder; Karissa Whiting; Li-Xuan Qin; Samuel Singer; Aimee M Crago; Joseph P Erinjeri
Journal:  Ann Surg Oncol       Date:  2021-07-16       Impact factor: 4.339

4.  Abdominal wall reconstruction after desmoid type fibromatosis radical resection: Case series from a single institution and review of the literature.

Authors:  S D Couto Netto; F Teixeira; C A M Menegozzo; A Albertini; E H Akaishi; E M Utiyama
Journal:  Int J Surg Case Rep       Date:  2017-03-01

5.  Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.

Authors:  Yoshihiro Nishida; Shunsuke Hamada; Hiroshi Urakawa; Kunihiro Ikuta; Tomohisa Sakai; Hiroshi Koike; Kan Ito; Ryo Emoto; Yuichi Ando; Shigeyuki Matsui
Journal:  Cancer Sci       Date:  2020-09-05       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.